Cohort Profile: The Mendelian Randomization in Pregnancy (MR-PREG) collaboration - Improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes

作者：Nancy McBride, Gemma Clayton, Ana Gonçalves Soares, Qian Yang, Tom A. Bond, Amy E. Taylor, Charikleia Chatzigeorgiou, Elizabeth Aiton, Jane West, Maria C. Magnus, Deborah A Lawlor, Maria Carolina Borges · 发表于：medRxiv · 年份：2025 · DOI：10.1101/2025.03.22.25324447 · 被引用次数：5 · 研究领域：Birth, Development, and Health

Abstract Purpose Adverse pregnancy and perinatal outcomes (APPOs), including pre-term birth, pre-eclampsia, and gestational diabetes, can result in maternal and neonatal morbidity and mortality, parental anxiety, and increased health care costs. Better understanding of causes of APPOs is essential to inform lifestyle and pharmaceutical interventions for their prevention and management. Given the difficulty of undertaking randomised control trials in pregnant women, triangulating evidence from across different methods with different sources of bias could improve our understanding of the causes of APPOs. The purpose of the Mendelian Randomization in Pregnancy (MR-PREG) collaboration is to support triangulation of evidence from genetic (e.g., Mendelian randomization [MR]) and non-genetic (e.g., partner negative controls) methods to explore causal effects of maternal exposures on a comprehensive set of APPOs Participants The MR-PREG collaboration includes individual participant data from three birth cohorts (two from the UK and one from Norway) and UK Biobank, and summary data from FinnGen and publicly available genome wide association studies (GWAS). We have harmonised data across studies so that currently includes exposures on up to 34 APPOs in up to 678,001 women. Findings to date The main aims of MR-PREG are to improve the evidence base for 1) prevention, by advancing our understanding of maternal modifiable causes of APPOs, 2) better understanding of the effect of pre-existi...